Clinical trial
Phase 1/2 Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusion in Patients With AJCC Stage IV Renal Cell Carcinoma
NCT00050323 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1/2 Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusion in Patients With AJCC Stage IV Renal Cell Carcinoma
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- November 30, 2002
- Completion date
- March 31, 2004
- Enrollment
- 30
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.